FDA
-
-
-
-
-
-
-
Rapt Therapeutics (RAPT) PT Raised to $41 at Clear Street
-
-
-
-
-
-
-
RAPT Therapeutics (RAPT): Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
-
-
-
-
-
-
-
RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients wit
-
-
-
-
-
322,090 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

